Aspen Neuroscience is a clinical stage, private biotechnology company developing iPSC-derived autologous (personalized) neuron replacement therapies for Parkinson’s disease (PD).
The lead product, ANPD001, has received Fast Track designation by the FDA, and is currently in a Phase 1/2a trial (ASPIRO) evaluating this iPSC-derived personalized dopaminergic neuronal precursor cell (DANPC) therapy for moderate to advanced PD.
Seed & Series A
Aspen was founded in 2018 with $6.5 million in seed funding led by Domain Associates and Axon Ventures and included Alexandria Venture Investments, ARCH Venture Partners, OrbiMed, and Section 32.
In early 2020 the company closed a Series A round of $70 million led by OrbiMed and included ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, Section 32, and Sam Altman.
Series B
In early 2022, the company closed a Series B round of $147 million. Google Ventures, LYFE Capital, and Revelation Partners co-led the investment round with participation from additional new investors ADIA, EDB Investments, MELLON, LifeForce Capital, Medical Excellence Capital Partners, Mirae Asset Capital, and NS Investment Co. The raise included significant participation from Series A/Seed investment teams including ARCH Venture Partners, OrbiMed Private Investments, Frazier Healthcare Partners, Alexandria Venture Investments, and Section32.
The Series B funding supported the planned studies of the company’s lead product candidate for Parkinson’s Disease, ANPD001, including its patient Screening Cohort study and the Phase 1/2a clinical trial, following IND submission to the FDA.
Series C
In November 2025, Aspen Neuroscience closed a Series C round of $115 million. OrbiMed, ARCH Venture Partners, Frazier Life Sciences, and Revelation Partners co-led the investment round, with participation from new investors including Kite, a Gilead Company, Balyasny Asset Management, Cormorant Asset Management, Prebys Ventures, and others. The round also included significant participation from existing investors Medical Excellence Capital, S32, and Axon Ventures. This latest funding brings Aspen’s total capital raised to date to over $340 million, including an $8 million grant from the California Institute for Regenerative Medicine (CIRM).
The Series C funding will support ongoing clinical trials of Aspen’s lead autologous cell therapy candidate for Parkinson’s disease, ANPD001, scale manufacturing capabilities to meet clinical and future commercial demand, and advance Aspen’s pipeline of iPSC-derived therapies for additional neurological indications.
For further information, please email us at IR@aspenneuro.com.
